Skip to main content
KBIO COMPANY Inc. logo

KBIO COMPANY Inc. — Investor Relations & Filings

Ticker · 038530 ISIN · KR7038530002 KO Manufacturing
Open in API
Filings indexed 440 across all filing types
Latest filing 2026-03-16 Proxy Solicitation & In…
Country KR South Korea
Listing KO 038530

About KBIO COMPANY Inc.

https://kbio.com/

KBio specializes in plant-based manufacturing of biologics. The company utilizes its proprietary RP3 platform, which leverages plants as biofoundries for the efficient and sustainable production of high-quality proteins, therapeutics, and other bioactive compounds. This innovative approach is designed to surpass traditional manufacturing limitations, enabling the rapid development and large-scale production of biomolecules. The company's focus includes developing novel product candidates such as antibody therapies to address public health challenges and areas of high unmet medical need.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for K-Bio Company. It contains the meeting agenda, details on voting procedures (including electronic voting), and management's report on business activities and financial statements. In the context of regulatory filings, this document is a Proxy Solicitation & Information Statement (PSI) as it provides shareholders with the necessary information to vote on board appointments, financial approvals, and other corporate matters at the upcoming AGM.
2026-03-16 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (Proxy Solicitation Statement) used to request shareholder votes for an upcoming Annual General Meeting. It contains the meeting agenda, proxy solicitation details, and financial statements (as required by the proxy solicitation regulations). It is not an Annual Report (10-K) or an Earnings Release (ER), but rather a specific proxy solicitation document (PSI).
2026-03-16 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Management Reports Classification · 95% confidence The document is a regulatory filing from a Korean company (K-Bio) disclosing a significant change in financial structure (revenue/profit/loss) exceeding 15% for a large corporation or 30% for others. This is a standard 'Earnings Release' (ER) format in the Korean market, providing key financial highlights (revenue, operating profit, net income) and the reasons for the change, prior to the final audited annual report. It fits the definition of an Earnings Release as it provides initial highlights of financial performance.
2026-02-27 Korean
[기재정정]주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) including the agenda items, date, and location. It also includes a correction notice (정정신고) regarding the agenda details. This type of document is standard for proxy solicitation and shareholder meeting information, which falls under the Proxy Solicitation & Information Statement category.
2026-02-25 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for K-Bio, detailing the date, location, and agenda items (financial statement approval, board remuneration, etc.). This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of upcoming voting matters, which falls under the Proxy Solicitation & Information Statement category.
2026-02-24 Korean
주식병합결정
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement from '케이바이오' (K-Bio) regarding a '주식병합결정' (Decision on Stock Consolidation/Reverse Stock Split). It details the change in par value, the reduction in the total number of shares, the timeline for the consolidation, and the purpose (stock price stabilization). This falls under capital structure changes, specifically share consolidation, which is categorized as 'SHA' (Share Issue/Capital Change).
2026-02-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.